Low-dose emapalumab treatment in refractory macrophage activation syndrome secondary to adult onset still’s disease/systemic lupus erythematosus: insights from nine cases
Our findings suggest that low-dose emapalumab may be a promising salvage option for refractory MAS in the Chinese population, but confirmation in larger prospective studies is required.
Authors
- Liyang Gu (ORCID: https://orcid.org/0009-0007-9116-0892)
- Liling Zhao (ORCID: https://orcid.org/0000-0003-0631-9162)
- Shuang Ye (ORCID: https://orcid.org/0000-0002-5257-5768)
- Qiong Fu (ORCID: https://orcid.org/0000-0001-5873-6422)
- Xinyue Lian (ORCID: https://orcid.org/0000-0002-1050-8911)
- Xiaodong Wang (ORCID: https://orcid.org/0000-0003-1215-6953)
- Ran Wang (ORCID: https://orcid.org/0000-0001-7857-8433)
- Yanwei Lin
- Haiting Wang (ORCID: https://orcid.org/0000-0002-5214-4458)
- Jie Chen (ORCID: https://orcid.org/0000-0003-0266-0929)
Institutions
- Renji Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1676749
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Renji Hospital